Latest Trials Latest NewsFAQ

BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of Nivolumab in Patients With Head and Neck Cancer.

Active, not recruiting

Conditions: Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck

Interventions: Biological: Nivolumab

First Posted Date: 2019-08-08

Last Posted Date: 2023-03-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 502

Registration Number: NCT04050761

Locations: 🇫🇷
Local Institution - 0001, Paris, France

A Study to Assess the Effectiveness of an Atrial Fibrillation (AF) Risk Prediction Algorithm and Diagnostic Test in Identifying Patients With AF.

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2019-08-05

Last Posted Date: 2021-08-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 260

Registration Number: NCT04045639

Locations: 🇬🇧
Local Institution, Worcester, United Kingdom

A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan

Conditions: Advanced or Metastatic Renal Cell Carcinoma

First Posted Date: 2019-08-02

Last Posted Date: 2022-05-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 286

Registration Number: NCT04043975

Locations: 🇯🇵
Local Institution - 0001, Tokyo, Japan

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

Phase 3

Active, not recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Nivolumab
Drug: Sorafenib
Drug: lenvatinib
Drug: Ipilimumab

First Posted Date: 2019-07-31

Last Posted Date: 2024-05-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 732

Registration Number: NCT04039607

Locations: 🇺🇸
Local Institution - 0295, Newark, New Jersey, United States
🇧🇷
Local Institution - 0061, Salvador, Bahia, Brazil
🇦🇺
Local Institution - 0038, Liverpool, New South Wales, Australia

and more 202 locations

Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Drug: Mycophenolate Mofetil

First Posted Date: 2019-07-31

Last Posted Date: 2020-06-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT04039373

Locations: 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

Phase 3

Active, not recruiting

Conditions: Psoriasis

Interventions: Drug: BMS-986165

First Posted Date: 2019-07-29

Last Posted Date: 2023-09-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1452

Registration Number: NCT04036435

Locations: 🇺🇸
First OC Dermatology & Belle-Aimee Skincare Clinic Fountain Valley, Fountain Valley, California, United States
🇺🇸
Local Institution - 0007, Miami Lakes, Florida, United States
🇺🇸
Radiant Research - Anderson, Anderson, South Carolina, United States

and more 267 locations

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Biological: durvalumab
Biological: nivolumab
Biological: ipilimumab

First Posted Date: 2019-07-19

Last Posted Date: 2024-12-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 925

Registration Number: NCT04026412

Locations: 🇺🇸
Local Institution - 0071, Burlington, Vermont, United States
🇺🇸
Local Institution - 0124, Cleveland, Ohio, United States
🇺🇸
Local Institution - 0053, Cincinnati, Ohio, United States

and more 176 locations

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: Nivolumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel
Drug: Placebo
Drug: Pemetrexed
Drug: Docetaxel

First Posted Date: 2019-07-19

Last Posted Date: 2024-07-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 461

Registration Number: NCT04025879

Locations: 🇺🇸
Local Institution - 0086, Traverse City, Michigan, United States
🇺🇸
Local Institution - 0103, Fredericksburg, Virginia, United States
🇨🇦
Local Institution - 0062, Oshawa, Ontario, Canada

and more 102 locations

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986256
Drug: Loestrin

First Posted Date: 2019-07-11

Last Posted Date: 2022-05-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT04016753

Locations: 🇺🇸
Altasciences Los Angeles (Formerly WCCT Global), Cypress, California, United States

An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986259
Other: Placebo
Diagnostic Test: P-Aminohippurate
Diagnostic Test: Iohexol

First Posted Date: 2019-07-05

Last Posted Date: 2021-04-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 132

Registration Number: NCT04008992

Locations: 🇳🇱
PRA Health Sciences - Groningen, Groningen, Netherlands
🇬🇧
Richmond Pharmacology, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy